1. Ashana DC, Umscheid CA, Stephens-Shields AJ, Kohn R, Madden V, Harhay MO, Chen Y, Kerlin MP. Determining the Association Between End-of-Life Care Resources and Patient Outcomes in Pennsylvania ICUs. Crit Care Med 2019.
2. Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, Pacher R. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail. 2007;9(2):202–8.
3. Koudouna E, Xanthos T, Bassiakou E, Goulas S, Lelovas P, Papadimitriou D, Tsirikos N, Papadimitriou L. Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Acta Anaesthesiol Scand. 2007;51(8):1123–9.
4. Kelm RF, Wagenfuhrer J, Bauer H, Schmidtmann I, Engelhard K, Noppens RR. Effects of levosimendan on hemodynamics, local cerebral blood flow, neuronal injury, and neuroinflammation after asphyctic cardiac arrest in rats. Crit Care Med. 2014;42(6):e410–9.
5. Onody P, Stangl R, Fulop A, Rosero O, Garbaisz D, Turoczi Z, Lotz G, Rakonczay Z Jr, Balla Z, Hegedus V, et al. Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury? PLoS One. 2013;8(9):e73758.
6. Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82–7.
7. Roehl AB, Hein M, Loetscher PD, Rossaint J, Weis J, Rossaint R, Coburn M. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010;10:97.
8. Lafci B, Yasa H, Ilhan G, Ortac R, Yilik L, Kestelli M, Goktogan T, Gurbuz A. Protection of the spinal cord from ischemia: comparative effects of levosimendan and iloprost. Eur Surg Res. 2008;41(1):1–7.
9. Klein KU, Boehme S, Hartmann EK, Szczyrba M, David M, Markstaller K, Engelhard K. A novel technique for monitoring of fast variations in brain oxygen tension using an uncoated fluorescence quenching probe (Foxy AL-300). J Neurosurg Anesthesiol. 2011;23(4):341–6.
10. Rudolph AM, Heymann MA. The circulation of the fetus in utero. Methods for studying distribution of blood flow, cardiac output and organ blood flow. Circ Res. 1967;21(2):163–84.
11. Morsbach S, Garcia-Bardon A, Kamuf J, Muller B, Beghersa N, Mohr K, Landfester K. Quantification of fluorescent dyes in organ tissue samples via HPLC analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1072:34–9.
12. Klein KU, Boehme S, Hartmann EK, Szczyrba M, Heylen L, Liu T, David M, Werner C, Markstaller K, Engelhard K. Transmission of arterial oxygen partial pressure oscillations to the cerebral microcirculation in a porcine model of acute lung injury caused by cyclic recruitment and derecruitment. Br J Anaesth. 2013;110(2):266–73.
13. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Bbttiger BW, Callaway C, Clark RS, Geocadin RG, Jauch EC, et al. Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication: A scientific statement from the International Liaison Committee on Resuscitation. the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke (Part 1). Int Emerg Nurs. 2009;17(4):203–25.
14. Varvarousi G, Stefaniotou A, Varvaroussis D, Aroni F, Xanthos T. The role of Levosimendan in cardiopulmonary resuscitation. Eur J Pharmacol. 2014;740:596–602.
15. Wu B, Peng YG, Zhao S, Bao N, Pan L, Dong J, Xu X, Wang Q. Supplement of levosimendan to epinephrine improves initial resuscitation outcomes from asphyxial cardiac arrest. BMC Anesthesiol. 2017;17(1):18.
16. Huang L, Weil MH, Tang W, Sun S, Wang J. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med. 2005;33(3):487–91.
17. Grossini E, Molinari C, Pollesello P, Bellomo G, Valente G, Mary D, Vacca G, Caimmi P. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376–88.
18. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med. 2001;29(11):2185–93.
19. Hein M, Zoremba N, Bleilevens C, Bruells C, Rossaint R, Roehl AB. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model. BMC Neurol. 2013;13:106.
20. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, Mik EG. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med. 2008;36(6):1886–91.
21. Klein KU, Schramm P, Glaser M, Reisch R, Tresch A, Werner C, Engelhard K. Intraoperative monitoring of cerebral microcirculation and oxygenation–a feasibility study using a novel photo-spectrometric laser-Doppler flowmetry. J Neurosurg Anesthesiol. 2010;22(1):38–45.
22. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol. 2001;428(3):311–4.
23. Sommer S, Leistner M, Aleksic I, Schimmer C, Alhussini K, Kanofsky P, Leyh RG, Sommer SP. Impact of levosimendan and ischaemia-reperfusion injury on myocardial subsarcolemmal mitochondrial respiratory chain, mitochondrial membrane potential, Ca2 + cycling and ATP synthesis. Eur J Cardiothorac Surg. 2016;49(2):e54–62. discussion e62.